The Global Diabetes Market:Therapeutics, Diagnostics and Complications

Table of Contents

1 Summary

2 The Diabetes Market

• 2.1 Current Market Size
  • 2.1.1 The Insulin Market
  • 2.1.2 The Non-Insulin Market
  • 2.1.3 Sales of Diabetes Products Could Double by 2012
  • 2.1.4 The Diabetic Neuropathy Market
  • 2.1.5 The Glucose Monitoring Market
• 2.2 Key Players in the Diabetes Market - Winners & Losers
  • 2.2.1 Key Players in the Insulin Market
  • 2.2.2 The Key Players in the Non-Insulin Market
  • 2.2.3 The Key Players in the Treatment of Diabetic Neuropathy
  • 2.2.4 The Key Players in the Glucose Monitoring Market
  • 2.2.5 Major players in the Diabetes Market in 2012

3 The Facts about Diabetes

• 3.1 What is Diabetes?
  • 3.1.1 Type 1 Diabetes
  • 3.1.2 Type 2 Diabetes
• 3.2 How is it Diagnosed?
• 3.3 What are the Current Treatment Goals?
• 3.4 The Financial Burden of Diabetes

4 Patient Statistics

• 4.1 Type 1 Diabetes Statistics
• 4.2 Type 2 Diabetes Statistics
• 4.3 Type 2 Pre-Diabetes
• 4.4 Diabetes Complications

5 Market Drivers

• 5.1 Patient Dynamics
• 5.2 Improvements in Diagnosis
• 5.3 Improvements in Glucose Monitoring
• 5.4 Changes in Guidelines
• 5.5 Launch of New Treatments & Combinations
• 5.6 Increased Use of Pen Devices
• 5.7 Off-Label Use

6 Market Resistors

• 6.1 More Economic Use of Insulin
• 6.2 Patent Expiration
• 6.3 Drug Safety Issues
• 6.4 Health Insurance/Reimbursement

7 Non-Insulin Agents: Attributes, Efficacy & Financial Forecasts

• 7.1 Oral Anti-Diabetic Agents (OADs)
  • 7.1.1 Insulin Secretion Promoting Agents
    • 7.1.1.1 Sulfonylureas (SUs) are Cost Effective in Early Type 2 Diabetes
      • 7.1.1.1.1 Advantages and Disadvantages of Sus
      • 7.1.1.1.2 Sales Forecast of Leading SUs 2005A-2012E
    • 7.1.1.2 Meglitinides (MGs) Have Limited Uptake in the Market
      • 7.1.1.2.1 Advantages and Disadvantages of MGs
      • 7.1.1.2.2 Sales forecast of leading MGs 2005A-2010E
  • 7.1.2 Insulin Sensitizing Agents
    • 7.1.2.1 Biguanides (BGs) are First-Line Therapy for Obese Diabetics
      • 7.1.2.1.1 Advantages and Disadvantages of BGs
      • 7.1.2.1.2 Sales Forecasts of Leading BGs 2005A-2012E
    • 7.1.2.2 Thiazolidinediones (TZDs) Extensively Used in the Second-Line Setting
      • 7.1.2.2.1 Advantages and Disadvantages of TZDs
  • 7.1.3 Combination Therapy
    • 7.1.3.1 Advantages of Combination Therapies
    • 7.1.3.2 Sales Forecast of Leading TZD Therapies 2005A-2012E
  • 7.1.4 Glucose Absorption Inhibitors
    • 7.1.4.1 Alpha-GIs are First Line Treatment in Japan
      • 7.1.4.1.1 Advantages and Disadvantages of Alpha Gis
      • 7.1.4.1.2 Sales Forecasts of Leading Alpha GIs 2005A-2012E
• 7.2 Insulin Secretion Promoting Agents
  • 7.2.1 Byetta is the First in Class
    • 7.2.1.1 Advantages and Disadvantages of Byetta
    • 7.2.1.2 Sales Forecasts of Approved Insulin Secretion Promoting Agents 2005A-2012E
• 7.3 Amylinomimetic Agents
  • 7.3.1 Symlin is the First Approved Amylinomimetic
    • 7.3.1.1 Advantages and Disadvantages of Symlin
    • 7.3.1.2 Sales Forecasts of Approved Amylinomimetic Agents 2005A-2012E
• 7.4 Prescription Trends in the Non-Insulin Market
• 7.5 Sales Forecast for Approved Non-Insulin Agents 2005A-2012E

8 Insulin Agents

• 8.1 Injectable Insulin
  • 8.1.1 Short Acting Insulin versus Rapid Acting Analogues
    • 8.1.1.1 Advantages and Disadvantages of Rapid Acting Insulin
  • 8.1.2 Rapid-Acting Analogues
    • 8.1.2.1 Humalog (Eli Lilly)
    • 8.1.2.2 Novolog (Novo Nordisk)
    • 8.1.2.3 Apidra (Sanofi Aventis)
  • 8.1.3 Sales Forecast of Leading Short and Rapid Acting Insulin 2005A-2012E
  • 8.1.4 Intermediate Acting Insulin vs Long Acting Analogues
    • 8.1.4.1 Advantages and Disadvantages of Intermediate-Acting Insulin
    • 8.1.4.2 Humulin (Eli Lilly)
    • 8.1.4.3 Novolin (Novo Nordisk)
    • 8.1.4.4 Insuman (Sanofi-Aventis)
    • 8.1.4.5 Sales Forecast of Intermediate Insulin 2005A-2012E
  • 8.1.5 Pre-Mixes
    • 8.1.5.1 Sales Forecast of Insulin Mixes 2005A-2012E
  • 8.1.6 Long Acting Insulin Analogues
    • 8.1.6.1 Lantus (Sanofi Aventis)
    • 8.1.6.2 Levemir (Novo Nordisk)
    • 8.1.6.3 Sales Forecast of Leading Long-Acting Analogues 2005A-2012E
• 8.2 Pulmonary Insulin
  • 8.2.1 Exubera (Pfizer/Nektar)
    • 8.2.1.1 Exubera's Unique Pharmacokinetic Profile
    • 8.2.1.2 Advantages and Disadvantages of Exubera
    • 8.2.1.3 Exubera due for launch July 2006
  • 8.2.2 Sales Forecast of Pulmonary Insulin 2005A-2012E
• 8.3 Prescription Trends In The Insulin Market
• 8.4 Sales Forecast for Approved Insulin Agents 2005A-2012E

9 Future Treatments: Non-Insulin

• 9.1 More Efficacious Medicine
• 9.2 Safer Anti-Diabetic Agents
• 9.3 Insulin-Secretion Promoting Agents
  • 9.3.1 Advantages and Disadvantages of Insulin Secretion Promoting Agents
  • 9.3.2 New GLP-1 Analogues
    • 9.3.2.1 Liraglutide (Novo Nordisk)
      • 9.3.2.1.1 Efficacy
      • 9.3.2.1.2 Safety
      • 9.3.2.1.3 Development and Filing
      • 9.3.2.1.4 Forecasts
    • 9.3.2.2 AVE-OO10 (Sanofi Aventis)
      • 9.3.2.2.1 Efficacy
      • 9.3.2.2.2 Safety
      • 9.3.2.2.3 Development and Filing
      • 9.3.2.2.4 Forecasts
    • 9.3.2.3 Byetta LAR (Eli Lilly)
      • 9.3.2.3.1 Efficacy
      • 9.3.2.3.2 Safety
      • 9.3.2.3.3 Development and Filing
      • 9.3.2.3.4 Forecasts
  • 9.3.3 Other GLP-1 Analogues in Early Stage Clinical Development
    • 9.3.3.1 BIM 51077
    • 9.3.3.2 CS-872
    • 9.3.3.3 CJC-113
    • 9.3.3.4 GSK716155
  • 9.3.4 New DPP IV inhibitors
    • 9.3.4.1 Galvus (Novartis)
      • 9.3.4.1.1 Efficacy
      • 9.3.4.1.2 Safety
      • 9.3.4.1.3 Development and Filing
      • 9.3.4.1.4 Forecasts
    • 9.3.4.2 Januvia (Merck & Co.)
      • 9.3.4.2.1 Efficacy
      • 9.3.4.2.2 Safety
      • 9.3.4.2.3 Development and Filing
      • 9.3.4.2.4 Forecasts
    • 9.3.4.3 Saxagliptin (Bristol-Myers Squibb)
      • 9.3.4.3.1 Efficacy
      • 9.3.4.3.2 Safety
      • 9.3.4.3.3 Development and Filing
      • 9.3.4.3.4 Forecasts
  • 9.3.5 Other DPP IV Inhibitors in Clinical Development
    • 9.3.5.1 SYR322 (Takeda)
    • 9.3.5.2 Denaglipitin (GSK)
    • 9.3.5.3 PSN9301 (Prosidion)
    • 9.3.5.4 Sales Forecasts of New Insulin-Secretion Promoting Agents 2005A-2010E
  • 9.3.6 New Insulin Sensitizing Agents
    • 9.3.6.1 Advantages and Disadvantages of Dual Acting PPAR Agonists and PPAR Pan Agonists
  • 9.3.7 New Dual Acting PPAR Agonists
    • 9.3.7.1 Pargluva (Bristol-Myers Squibb)
      • 9.3.7.1.1 Efficacy
      • 9.3.7.1.2 Safety
      • 9.3.7.1.3 Development and Filing
      • 9.3.7.1.4 Forecasts
    • 9.3.7.2 Naveglitazar (Eli Lilly/Ligand)
      • 9.3.7.2.1 Efficacy
      • 9.3.7.2.2 Safety
      • 9.3.7.2.3 Development and Filing
      • 9.3.7.2.4 Forecasts
  • 9.3.8 Other dual acting PPAR agonists
    • 9.3.8.1 AVE-0847 (Sanofi Aventis)
    • 9.3.8.2 TAK-654 (Takeda)
    • 9.3.8.3 ONO-5129 (ONO Pharma)
  • 9.3.9 New PPAR Pan Agonists
    • 9.3.9.1 GW677954 (GSK)
    • 9.3.9.2 PLX204 (Plexxikon)
  • 9.3.10 New PPAR Gamma Agonists
    • 9.3.10.1 Rivoglitazone (Daiichi-Sankyo)
    • 9.3.10.2 Balaglitazone (Dr Reddy)
    • 9.3.10.3 CLX-0921 (Calyx Pharmaceuticals)
    • 9.3.10.4 Metaglidasen (Metabolex)
    • 9.3.10.5 AMG 131 (Amgen)
  • 9.3.11 New PPAR agonist combinations
  • 9.3.12 Sales Forecasts of New Insulin Sensitizing Agents 2005A-2012E

10 Future Treatments: Insulin

• 10.1 Pulmonary Insulin
  • 10.1.1 AERx iDMS (Novo Nordisk/Paradigm)
    • 10.1.1.1 Efficacy
    • 10.1.1.2 Safety
    • 10.1.1.3 Development and Filings
    • 10.1.1.4 Forecasts
  • 10.1.2 TechnoSphere Inhaled Insulin (MannKind Corporation)
    • 10.1.2.1 Efficacy
    • 10.1.2.2 Safety
    • 10.1.2.3 Development and filings
    • 10.1.2.4 Forecasts
  • 10.1.3 AIR inhaled Insulin (Eli Lilly/Alkermes)
    • 10.1.3.1 Efficacy
    • 10.1.3.2 Safety
    • 10.1.3.3 Development and Filings
    • 10.1.3.4 Forecasts
  • 10.1.4 Other Pulmonary Insulin in Clinical Development
    • 10.1.4.1 Kos Pharmaceuticals
    • 10.1.4.2 QDose Pharmaceuticals
    • 10.1.4.3 Coremed Inc
• 10.2 Oral Insulin
  • 10.2.1 Oral-Lyn/Oralgen/Oralin (Generex)
  • 10.2.2 Oral Insulin (Hubei Huagong Biochemical Engineering)
• 10.3 Transoral Patch Insulin
  • 10.3.1 ALT 1391 (Altea Therapeutics)
  • 10.3.2 Transoral Insulin Patch (Noven Pharmaceuticals)
• 10.4 Sales Forecasts of New Insulin Formulations

11 Alternative Approaches to the Treatment of Diabetes

• 11.1 The Sodium-Dependent Glucose Transporter Inhibitors (SGLT inhibitors)
  • 11.1.1 The SGLT 1 inhibitors
  • 11.1.2 The SGLT 2 inhibitors
• 11.2 Protein Tyrosine Phosphatase Inhibitors (PTP ase)
• 11.3 The Glycogenolysis/Gluconeogenesis Modulators
  • 11.3.1 Glycogen phosphorylase inhibitors
  • 11.3.2 Fructose-biphosphatase inhibitors
  • 11.3.3 Glucagon receptor antagonists
  • 11.3.4 Glucokinase activators
• 11.4 Sales Forecasts of Alterative Diabetes Therapies

12 Treatments for Diabetes Complications

• 12.1 Diabetic Retinopathy
• 12.2 Diabetic Nephropathy
• 12.3 Diabetic Neuropathy
• 12.4 Current Treatments for Diabetic Complications
  • 12.4.1 Antihypertensive use in Diabetic Nephropathy
  • 12.4.2 Anticonvulsant use in Diabetic Neuropathy
  • 12.4.3 Antidepressant use in Diabetic Neuropathy
• 12.5 New Treatments for Diabetic Complications
  • 12.5.1 Arxxant (Eli Lilly)
    • 12.5.1.1 Efficacy
    • 12.5.1.2 Safety
    • 12.5.1.3 Development & Filing
    • 12.5.1.4 Forecasts
  • 12.5.2 Avosentan (Speedel)
    • 12.5.2.1 Efficacy
    • 12.5.2.2 Safety
    • 12.5.2.3 Development and Filing
    • 12.5.2.4 Forecasts
  • 12.5.3 Candesartan (Takeda/AstraZeneca)
  • 12.5.4 Fidarestat (Sankyo/Sanwa Kagaku Kenkyusho)
  • 12.5.5 Neurodex (Avanir)
    • 12.5.5.1 Efficacy
    • 12.5.5.2 Safety
    • 12.5.5.3 Development and filing
  • 12.5.6 Perzinfotel (Wyeth)
  • 12.5.7 Ranirestat (Dainippon Sumitomo/Eisai)
  • 12.5.8 Rasilez (Novartis/Speedel)
    • 12.5.8.1 Efficacy
    • 12.5.8.2 Safety
    • 12.5.8.3 Development & Filing
    • 12.5.8.4 Forecasts
  • 12.5.9 Sulonex (Keryx)
    • 12.5.9.1 Efficacy
    • 12.5.9.2 Safety
    • 12.5.9.3 Development & Filing
    • 12.5.9.4 Sales forecasts and Assumptions
  • 12.5.10 Sativex (GW Pharma)
  • 12.5.11 TAK 428 (Takeda)
  • 12.5.12 V3381 (Vernalis)
• 12.6 Drugs in Early Phase Clinical Development For Diabetic Complications
  • 12.6.1 ABT-894 (Abbott)
  • 12.6.2 AV-101 (VistaGen)
  • 12.6.3 CNS 5161 (CeNeS)
  • 12.6.4 SB-509 (Sangamo BioSciences)
• 12.7 Sales forecasts of Key Drugs to Treat Diabetic Complications

13 The Diabetes Diagnostic Market

• 13.1 The Glucose Monitoring Market
  • 13.1.1 Self-Monitoring of Blood Glucose
  • 13.1.2 Glucose Meters
  • 13.1.3 Non-Invasive Testing
  • 13.1.4 Continuous Blood Glucose Monitoring
• 13.2 The Insulin Delivery Market

14 Company Profiles

• Abbott Laboratories
• Amylin Pharmaceuticals Inc
• Bristol-Myers Squibb
• Bayer Group
• Eli Lilly and Company
• F. Hoffman-La Roche Ltd
• GlaxoSmithKline plc
• Keryx Biopharmaceuticals
• LifeScan Inc
• Medtronic Inc.
• Merck & Co.Inc
• Novartis Pharmaceuticals
• Novo Nordisk A/S
• Pfizer
• Sanofi-Aventis
• Takeda Pharmaceutical Company Ltd